Apellis Pharmaceuticals Is A Global Biopharmaceutical Company Based In Walthammassachusettsthe Company Is Focused On Developing Innovative Therapies That Target The Complement Systema Crucial Part Of The Immune Systemapellis Aims To Create Life Changing Treatments For Various Debilitating Diseases Through Its Commitment To Scientific Research And Patient Care The Company Has A Diverse Pipeline Of Productsincluding Empaveliwhich Is Approved For Treating Paroxysmal Nocturnal Hemoglobinuria And Is Being Investigated For Other Conditionssyfovre Is In Development For Geographic Atrophyalong With A Combination Therapy Involving Apl Apl 3007Apellis Is Also Exploring Rna Therapies And Gene Edited Treatments For Multiple Therapeutic Areas With A Global Presence In Countries Such As The Uscanadaand Several European Nationsapellis Serves Patients And Healthcare Providers Affected By Diseases Related To The Complement Systemthe Company Reported Approximately $709 Million In U Snet Product Revenues For The Full Year 2024Reflecting Its Strong Market Position And Commitment To Advancing Its Therapeutic Offerings
